Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
Share
-
A
+
A
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
You are here
Home
Most Viewed Papers
Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis.
Commentary: Outcome measures were flawed.
Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission.
Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.
Neuromyelitis optica: not a multiple sclerosis variant.
Neuroimmunology: Clostridium-reactive T cells are implicated in the pathogenesis of neuromyelitis optica.
Pathogenic implications of iron accumulation in multiple sclerosis.
A Safety and Efficacy Extension Study of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (DreaMS)
Microcystic macular oedema in multiple sclerosis is associated with disease severity.
Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis.
LINGO-1, A TRANSMEMBRANE SIGNALING PROTEIN, INHIBITS OLIGODENDROCYTE DIFFERENTIATION AND MYELINATION THROUGH INTERCELLULAR SELF-INTERACTIONS.
Immunosuppressive properties of mesenchymal stem cells: advances and applications.
Eight cases of insular sclerosis of the brain and spinal cord.
Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
The Histology of Disseminated Sclerosis
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.
Multiple sclerosis from the standpoint of geographic distribution and race
Safety study of BIIB033 in subjects with multiple sclerosis
Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease.
Critical Review: disseminated sclerosis
Pathological Anatomy: Illustrations of the elementary forms of disease.
Risk factors for multiple sclerosis: decreased vitamin D level and remote Epstein-Barr virus infection in the pre-clinical phase of multiple sclerosis.
The mystery of missing heritability: Genetic interactions create phantom heritability.
The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »